NCT01322945 · STUDY IN CONTEXT

Barrow Nasal Inventory Survey

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Mean survey response at 90 days post surgery between the control patients and the endonasal surgery patients using the Anterior skull base nasal inventory (ASK Nasal Inventory. A 5-point Likert scale for each question on the ASK Nasal inventory measures frequency of nasal symptoms where 1=never, 2= a little of the time, 3=some of the time, 4=most of the time, 5= all of the time. Total mean Likert scores were compared in the endonasal group to the control group after surgery. Scores range from minimum of 9 to maximum of 45. The lower the score the fewer the nasal complaints.

Power analyses were conducted to determine a sample size large enough to significantly detect change with 90% power using a pre- post research methodology.

→

secondary · POSTED

First 12 endonasal and 10 control patients enrolled in the study completed the ASK Nasal Inventory at 90 days and 120 days post surgery to measure reliablity of the survey (they scored the 9-item instrument similarly at both time frames)comparing 5-point Likert scale scores. Pearson correlation was used to determine a correlation between each patient's responses at 90 days post op and 120 days post op.

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-pituitary-tumors
nct id: NCT01322945
trial label: Barrow Nasal Inventory Survey
applicability: narrower
applicability note: Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 2
harms Count: 2
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-pituitary-tumors
nct id
NCT01322945
outcome key
om-0000
source section id
NCT01322945-om-0000
source outcome index
0
endpoint
Change in Mean Survey Response From Baseline to 90 Days Post Surgery
endpoint definition
Mean survey response at 90 days post surgery between the control patients and the endonasal surgery patients using the Anterior skull base nasal inventory (ASK Nasal Inventory. A 5-point Likert scale for each question on the ASK Nasal inventory measures frequency of nasal symptoms where 1=never, 2= a little of the time, 3=some of the time, 4=most of the time, 5= all of the time. Total mean Likert scores were compared in the endonasal group to the control group after surgery. Scores range from minimum of 9 to maximum of 45. The lower the score the fewer the nasal complaints.
time origin
Baseline, 90 days post surgery
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Power analyses were conducted to determine a sample size large enough to significantly detect change with 90% power using a pre- post research methodology.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-pituitary-tumors
nct id
NCT01322945
outcome key
om-0001
source section id
NCT01322945-om-0001
source outcome index
1
endpoint
Test-retest Reliability of the ASK Nasal Inventory
endpoint definition
First 12 endonasal and 10 control patients enrolled in the study completed the ASK Nasal Inventory at 90 days and 120 days post surgery to measure reliablity of the survey (they scored the 9-item instrument similarly at both time frames)comparing 5-point Likert scale scores. Pearson correlation was used to determine a correlation between each patient's responses at 90 days post op and 120 days post op.
time origin
90 days and 120 days post surgery
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-pituitary-tumors
nct id
NCT01322945
outcome key
om-0000
arm key
OG000
arm label
Endonasal Group
regimen
Patients undergoing endonasal surgery for anterior skull base tumors, pituitary tumors, and skull base spinal fluid leaks using endonasal techniques.
analyzed count
52
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01322945-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-pituitary-tumors
nct id
NCT01322945
outcome key
om-0000
arm key
OG001
arm label
Control Group
regimen
Patients undergoing any neurosurgical procedure requiring general anesthesia that did not involve the endonasal corridor, such as spinal decompression procedures, craniotomies for trigeminal neuralgia, or shunting procedures.
analyzed count
42
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01322945-om-0000#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-pituitary-tumors
nct id
NCT01322945
outcome key
om-0001
arm key
OG000
arm label
Endonasal Group
regimen
First 12 patients enrolled undergoing endonasal surgery for anterior skull base tumors, pituitary tumors, and skull base spinal fluid leaks using endonasal techniques.
analyzed count
12
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01322945-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-pituitary-tumors
nct id
NCT01322945
outcome key
om-0001
arm key
OG001
arm label
Control Group
regimen
First 10 patients enrolled undergoing any neurosurgical procedure requiring general anesthesia that did not involve the endonasal corridor, such as spinal decompression procedures, craniotomies for trigeminal neuralgia, or shunting procedures.
analyzed count
10
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01322945-om-0001#groups/OG001

harms

release id
clinical-indications-draft-1
disease state id
ds-pituitary-tumors
nct id
NCT01322945
harm key
EG000
source section id
NCT01322945-ae
event group key
EG000
event group label
Endonasal Group
serious affected
0
serious at risk
52
other affected
0
other at risk
52
frequency threshold
0
collection period
Source null
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-pituitary-tumors
nct id
NCT01322945
harm key
EG001
source section id
NCT01322945-ae
event group key
EG001
event group label
Control Group
serious affected
0
serious at risk
42
other affected
0
other at risk
42
frequency threshold
0
collection period
Source null
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice